Matarin Capital Management’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Matarin Capital Management’s Portfolio MNTA Stock Details MNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-159,527	Closed	-$2.23M	–	320
2017 Q4	$2.23M	Sell	159,527 -79,183	-33%	-$1.07M	0.17%	167
2017 Q3	$4.42M	Buy	238,710 +17,797	+8%	+$298K	0.38%	108
2017 Q2	$3.73M	Buy	220,913 +116,538	+112%	+$1.77M	0.35%	129
2017 Q1	$1.39M	Buy	+104,375	New	+$1.63M	0.14%	183
2014 Q1	–	Sell	-97,728	Closed	-$1.73M	–	178
2013 Q4	$1.73M	Buy	97,728 +32,621	+50%	+$548K	1.06%	43
2013 Q3	$937K	Buy	65,107 +12,969	+25%	+$198K	0.79%	56
2013 Q2	$785K	Buy	+52,138	New	+$688K	0.79%	48

Other funds holding MNTA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Matarin Capital Management's MNTA Position: Q1 2018 in Review

Matarin Capital Management sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q1 2018, closing a stake of 159,527 shares — an estimated $2.23M sold.

Matarin Capital Management first reported a position in MNTA in Q2 2013 and held it in 7 quarters. The position peaked at $4.42M in Q3 2017. 163 funds tracked by Wall St. Rank hold MNTA as of Q1 2018.

Matarin Capital Management reported no remaining Momenta Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
Matarin Capital Management sold 159,527 Momenta Pharmaceuticals, Inc. shares in Q1 2018, an estimated $2.23M.
Matarin Capital Management first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2013 and held it in 7 quarters.
Matarin Capital Management's Momenta Pharmaceuticals, Inc. position peaked at $4.42M in Q3 2017.
163 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q1 2018.

Based on Matarin Capital Management's 13F filing for Q1 2018, filed 10 May 2018.